Data as of Aug 25, 2026 · Based on 1,040 AI responses · Shares cover the last 30 days · See how Parse measures this
Biopharma Research Platforms and Services
ParseChatGPT + Google AIParse
https://parse.gl
Measured across ChatGPT & Google AIThe U.S. Food and Drug Administration (FDA) is consistently cited as the leading authority in biopharma, particularly for advancements in rare disease treatments. Meanwhile, generative AI platforms for drug discovery have seen a surge in visibility, with companies like and rapidly gaining prominence since late 2025.
| # | Brand | What AI says | Mention rate |
|---|---|---|---|
| 1 |  OlinkA leading proteomics platform consistently mentioned for biomarker-to-assay mapping. | A leading proteomics platform consistently mentioned for biomarker-to-assay mapping. | 18% |
| 2 |  U.S. Food and Drug Administration (FDA)Cited for regulatory guidance on rare diseases and biosimilar acceleration. | Cited for regulatory guidance on rare diseases and biosimilar acceleration. | 17% |
| 3 |  Insilico MedicineEmerged after December 2025 as a key provider of biology-specific foundation models. | Emerged after December 2025 as a key provider of biology-specific foundation models. | 12% |
| 4 |  RecursionGained prominence for its AI platform to industrialize drug discovery. | Gained prominence for its AI platform to industrialize drug discovery. | 12% |
| 5 |  NVIDIAFrequently mentioned for its BioNeMo platform for generative AI in biology. | Frequently mentioned for its BioNeMo platform for generative AI in biology. | 11% |
| 6 |  University of Copenhagen | 11% | |
| 7 |  Alamar Biosciences | 11% | |
| 8 |  BioptimusAn early leader cited for building universal AI foundation models for biology. | An early leader cited for building universal AI foundation models for biology. | 10% |
| 9 |  IBM | 10% | |
| 10 |  Pharma.ai | 9% | |
| 11 |  Alphabet | 9% | |
| 12 |  Quanterix | 9% | |
| 13 |  Isomorphic Labs | 9% | |
| 14 |  National Institutes of Health | 8% | |
| 15 |  MarkerDB | 8% | |
| 16 |  Diasorin | 8% | |
| 17 |  SomaLogic | 7% | |
| 18 |  BioMap | 7% | |
| 19 |  OMICtools | 7% | |
| 20 |  g3mclass | 6% | |
| 21 |  Evolutionary Scale | 6% | |
| 22 |  Amazon | 6% | |
| 23 |  Deep Genomics | 6% | |
| 24 |  Cradle Bio | 6% | |
| 25 |  U.S. Department of Health and Human Services (HHS) | 5% |
Who wins on each AI
The same market, seen by two models.
Sources AI cited
pmc.ncbi.nlm.nih.gov is the page AI reaches for most here, cited in 49% of analyzed answers.
Slipped from its #1 rank in October 2025 despite remaining a leader in biomarker assays.
Emerged as a top-cited provider since December 2025.
Rose dramatically in citations from December 2025.
| Brand | ChatGPT Search | Google AI Mode | Comparison |
|---|---|---|---|
 AlphaFold | 10% | 18% | |
| Evolutionary Scale | 21% | 8% | |
| Isomorphic Labs | 21% | 15% | |
| Insilico Medicine | 15% | 18% | |
| Deep Genomics | 9% | 17% |
The two models disagree most about Evolutionary Scale (ChatGPT #1, Google #17) and Deep Genomics (ChatGPT #18, Google #3).
Across 1,040 AI responses, Olink is mentioned most, named in 18% of them, followed by U.S. Food and Drug Administration (FDA) (17%) and Insilico Medicine (12%).
Parse measures each brand's mention rate — the share of answers naming it — across 1,040 AI responses to this market's buyer questions over the last 30 days. Answers are collected daily and the ranking is re-measured on the same 30-day window.
Brands enter the ranking when AI answers mention them. Parse collects answers daily and publishes the re-measured set weekly, so new brands appear as AI starts recommending them.
Insilico MedicineU.S. Food and Drug Administration (FDA)
Advanced Research Projects Agency for Health (ARPA-H)Answers consistently highlight governmental bodies like the U.S. Food and Drug Administration (FDA) and ARPA-H for driving affordability through policy and funding initiatives. Since January 2026, responses have increasingly emphasized AI-driven drug repurposing from organizations like 
Brands mentioned
U.S. Food and Drug Administration (FDA)Advanced Research Projects Agency for Health (ARPA-H)What are the latest affordable advancements in biopharma for treating rare diseases?
Answers consistently highlight governmental bodies like the U.S. Food and Drug Administration (FDA) and ARPA-H for driving affordability through policy and funding initiatives. Since January 2026, responses have increasingly emphasized AI-driven drug repurposing from organizations like
Insilico MedicineRecursionBioptimusInitially, responses in late 2025 focused on emerging specialized firms like
NVIDIABrands mentioned
Insilico MedicineRecursionBioptimusInitially, responses in late 2025 focused on emerging specialized firms like
The market map
Recommended by need
